Ribomic (TSE:4591) Other Long Term Assets: 円36.73 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4591 Ribomic Inc TSE:4591
32 GF Score
Price 円77.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Other Long Term Assets?

Ribomic TSE:4591 +2.67% 32 Other Long Term Assets is 円36.73 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Ribomic's other long-term assets for the quarter that ended in Mar. 2026 was 円36.73 Mil.

Ribomic's quarterly other long-term assets increased from Sep. 2025 (円39.16 Mil) to Dec. 2025 (円50.29 Mil) but then stayed the same from Dec. 2025 (円50.29 Mil) to Mar. 2026 (円36.73 Mil).

Ribomic's annual other long-term assets declined from Mar. 2024 (円29.23 Mil) to Mar. 2025 (円27.00 Mil) but then increased from Mar. 2025 (円27.00 Mil) to Mar. 2026 (円36.73 Mil).

Ribomic Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Ribomic's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Other Long Term Assets Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 29.95 29.23 27.00 36.73

Ribomic Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.00 39.26 39.16 50.29 36.73
TSE:4591
32GF Score
Ribomic Inc TSE:4591
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of 円36.73 Mil mean?
Ribomic (TSE:4591) has a Other Long Term Assets of 円36.73 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ribomic and its competitors.
Is Ribomic's Other Long Term Assets too high?
Ribomic's current Other Long Term Assets is 円36.73 Mil. Overall, Ribomic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Other Long Term Assets compare to VRTX and REGN?
Ribomic's Other Long Term Assets of 円36.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ribomic and its competitors. Ribomic's current Other Long Term Assets is 円36.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Other Long Term Assets of 円36.73 Mil. The current Other Long Term Assets is 円36.73 Mil. Ribomic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Other Long Term Assets is 円36.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
32GF Score

Get the complete analysis for TSE:4591

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price